Back to results

Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy

Primary Purpose

Colon Adenocarcinoma

Status

Completed

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

Carbon C 14 Oxaliplatin

Oxaliplatin

About this trial

This is an interventional treatment trial for Colon Adenocarcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Histologically or cytologically confirmed locally advanced or metastatic colon or rectal adenocarcinoma
Intent to treat the patient with a leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy regimen containing fluorouracil (5-FU), leucovorin, and oxaliplatin according to clinical standard practice; the intent should be to dose oxaliplatin at 85 mg/m^2 on an every 2 week basis
Treatment with any additional Food and Drug Administration (FDA)-approved biologic agent (i.e. bevacizumab, cetuximab, or panitumumab) is allowed according to standard practice
Prior radiation or surgery is allowed, but should be finished at least 2 weeks prior to study enrollment; if a participant has prior radiation therapy, at least one measurable lesion outside of the radiation field should be available for the evaluation of response to chemotherapy
Any number of prior therapies other than oxaliplatin is allowed
Zubrod performance status equal to or less than 2 (Karnofsky equal to or greater than 50%)
Life expectancy of at least 3 months
Absolute neutrophil count greater than or equal to 1,500/microL
Platelets greater than or equal to 100,000/microL
Total bilirubin less than 3 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase) less than or equal to 5 x ULN
Creatinine less than 1.5 x ULN
Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative
Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after study participation
Men must agree to use adequate contraception (barrier method or abstinence) prior to study entry and for 30 days after study participation
Ability to understand and willing to sign a written informed consent document

Exclusion Criteria:

Prior treatment with oxaliplatin
Patients must not receive concomitant radiation
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Participants who are pregnant or nursing
Participants who are allergic to any platinum agent
Participants who have more than grade 1 peripheral neuropathy

Sites / Locations

University of California Davis Comprehensive Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

carbon C 14 oxaliplatin and oxaliplatin

Arm Description

Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.

Outcomes

Primary Outcome Measures

Feasibility of 14C Oxaliplatin Microdose as a Clinical Assay to Predict Oxaliplatin Exposure

Correlate area under curve from phase 0 microdosing with area under curve for therapeutic dose of oxaliplatin

Secondary Outcome Measures

Duration of Disease Control (DDC) According to RECIST 1.1

Will characterize the repair of DNA adducts in PBMC, using descriptive statistics.

Number of Participants With Adverse Events According to CTCAE Version 4

Assess toxicity to both microdoses of carbon C 14 oxaliplatin. Toxicities potentially related to carbon C 14 oxaliplatin will be assessed from initiation of the study to at least 14 days after the administration of the FOLFOX-integrated microdose or until full recover of toxicity (whichever is longer). Safety will be assessed through summaries of adverse events and laboratory evaluations.

Response Rate Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Response was determined according to RECIST criteria as either partial response (PR) or one almost complete response (CR) or progressive disease (PD).

Full Information

NCT ID

NCT02569723

First Posted

July 27, 2015

Last Updated

March 4, 2021

Sponsor

Edward Kim

Collaborators

National Cancer Institute (NCI)

1. Study Identification

Unique Protocol Identification Number

NCT02569723

Brief Title

Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy

Official Title

Pilot Study of a Carbon 14 Oxaliplatin Microdosing Assay to Predict Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer

Study Type

Interventional

2. Study Status

Record Verification Date

March 2021

Overall Recruitment Status

Completed

Study Start Date

October 16, 2015 (Actual)

Primary Completion Date

April 20, 2018 (Actual)

Study Completion Date

April 4, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor-Investigator

Name of the Sponsor

Edward Kim

Collaborators

National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This pilot clinical trial studies how well carbon C 14 oxaliplatin microdosing assay works in predicting exposure and sensitivity to oxaliplatin-based chemotherapy in patients with colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carbon C 14 is a radioactive form of carbon, exists in nature and in the body at a low level. Microdose carbon C 14 oxaliplatin diagnostic assay may help doctors understand how well patients respond to treatment and develop individualize oxaliplatin dosing in patients with colorectal cancer.

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate the feasibility of [14C] (carbon C 14) oxaliplatin microdose as a clinical assay to predict oxaliplatin exposure. SECONDARY OBJECTIVES: I. To estimate the degree to which a [14C]oxaliplatin microdose predicts the observed pharmacokinetics of standard dose oxaliplatin. II. To validate that intrapatient variation of exposure to a [14C]oxaliplatin microdose is less than 5%. III. To detect the levels of oxaliplatin-deoxyribonucleic acid (DNA) adducts induced by oxaliplatin microdosing in peripheral blood mononuclear cells (PBMCs), and correlate the results with patient response and progression free survival on oxaliplatin-based chemotherapy. IV. To develop preliminary safety data of [14C]oxaliplatin microdosing for future studies. OUTLINE: Patients receive carbon C 14 oxaliplatin microdose intravenously (IV) over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Colon Adenocarcinoma

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

6 (Actual)

8. Arms, Groups, and Interventions

Arm Title

carbon C 14 oxaliplatin and oxaliplatin

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Carbon C 14 Oxaliplatin

Other Intervention Name(s)

[14C] Oxaliplatin

Intervention Description

Intravenous infusion

Intervention Type

Drug

Intervention Name(s)

Oxaliplatin

Other Intervention Name(s)

Eloxatin

Intervention Description

Intravenous infusion

Primary Outcome Measure Information:

Title

Feasibility of 14C Oxaliplatin Microdose as a Clinical Assay to Predict Oxaliplatin Exposure

Description

Correlate area under curve from phase 0 microdosing with area under curve for therapeutic dose of oxaliplatin

Time Frame

0-5 minutes predose, 5, 15, and 30 minutes, and at 1, 2, 4, 8, and 24 hours after carbon C 14 oxaliplatin microdose

Secondary Outcome Measure Information:

Title

Duration of Disease Control (DDC) According to RECIST 1.1

Description

Will characterize the repair of DNA adducts in PBMC, using descriptive statistics.

Time Frame

Up to 2 years

Title

Number of Participants With Adverse Events According to CTCAE Version 4

Description

Time Frame

Approximately 2 months

Title

Response Rate Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Description

Response was determined according to RECIST criteria as either partial response (PR) or one almost complete response (CR) or progressive disease (PD).

Time Frame

Up to 2 years

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Histologically or cytologically confirmed locally advanced or metastatic colon or rectal adenocarcinoma Intent to treat the patient with a leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy regimen containing fluorouracil (5-FU), leucovorin, and oxaliplatin according to clinical standard practice; the intent should be to dose oxaliplatin at 85 mg/m^2 on an every 2 week basis Treatment with any additional Food and Drug Administration (FDA)-approved biologic agent (i.e. bevacizumab, cetuximab, or panitumumab) is allowed according to standard practice Prior radiation or surgery is allowed, but should be finished at least 2 weeks prior to study enrollment; if a participant has prior radiation therapy, at least one measurable lesion outside of the radiation field should be available for the evaluation of response to chemotherapy Any number of prior therapies other than oxaliplatin is allowed Zubrod performance status equal to or less than 2 (Karnofsky equal to or greater than 50%) Life expectancy of at least 3 months Absolute neutrophil count greater than or equal to 1,500/microL Platelets greater than or equal to 100,000/microL Total bilirubin less than 3 x institutional upper limit of normal (ULN) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase) less than or equal to 5 x ULN Creatinine less than 1.5 x ULN Women of child bearing potential must not be pregnant; a pre-study pregnancy test must be negative Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after study participation Men must agree to use adequate contraception (barrier method or abstinence) prior to study entry and for 30 days after study participation Ability to understand and willing to sign a written informed consent document Exclusion Criteria: Prior treatment with oxaliplatin Patients must not receive concomitant radiation Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Participants who are pregnant or nursing Participants who are allergic to any platinum agent Participants who have more than grade 1 peripheral neuropathy

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Edward Kim

Organizational Affiliation

University of California, Davis

Official's Role

Principal Investigator

Facility Information:

Facility Name

University of California Davis Comprehensive Cancer Center

City

Sacramento

State/Province

California

ZIP/Postal Code

95817

Country

United States

12. IPD Sharing Statement

Learn more about this trial

Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy

We'll reach out to this number within 24 hrs